Intelligence coverage: 65%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

ZBH

ZIMMER BIOMET HOLDINGS, INC.

Healthcare · Medical Devices

$91.34Sep 29, 2026

AI confidence 70% · prior close shown (market closed)

Investment Snapshot

Weak evidence · 1 source

Why it matters

ZIMMER BIOMET HOLDINGS, INC. shows stable business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +5% YoY in Q2 FY2026.

TrajectoryStable

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

  • Revenue +5% YoY in Q2 FY2026

Pipeline evidence · 22d ago

ZBH's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on ZBH.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full ZBH earnings analysis

Reported figures for ZIMMER BIOMET HOLDINGS, INC. — research only, not investment advice.

Revenue YoY
+4.8%
EPS YoY
+33.8%

Latest Intelligence

Updated

What happened recently for ZIMMER BIOMET HOLDINGS, INC. (ZBH) — events, not interpretation.

Event
Reported Q2 2026 revenue +5% YoY.
Also
Last session September 29, 2026 at $91.34.
Source
Q2 2026 earnings

Research & analysis only — not investment advice.

Loading earnings intelligence…

ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Healthcare · Medical Devices

Investment Snapshot above is the primary AlphaOS analysis for ZIMMER BIOMET HOLDINGS, INC. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.

Key facts

Sector:
Healthcare
Market cap:
$17.42B
Revenue:
$2.09B

ZBH earnings analysis

Research & analysis only — not investment advice. Price, charts, and filings are above.

Connected intelligence

Follow ZIMMER BIOMET HOLDINGS, INC. through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.

Connected companies and research pages from the AlphaOS knowledge graph.

Structured stock intelligence for companies connected to this research.